O.6Pre-clinical development of SPK-3006, an investigational liver-directed AAV gene therapy for the treatment of Pompe disease
Sean M. Armour(Spark Therapeutics (United States)), Federico Mingozzi(Spark Therapeutics (United States)), Xavier M. Anguela(Children's Hospital of Philadelphia), Marco Crosariol(Spark Therapeutics (United States)), Christopher Riling(Spark Therapeutics (United States)), Helena Costa Verdera(Spark Therapeutics (United States)), Fanny Collaud(Inserm), Giuseppe Ronzitti(Inserm), Jayme M.L. Nordin(Spark Therapeutics (United States)), Hayley A. Hanby(Spark Therapeutics (United States)), Pauline Sellier(Inserm), Pasqualina Colella(Stanford Medicine), William J. Quinn(University of Pennsylvania), Francesco Puzzo(Inserm), Umut Cagin(Inserm), Daniëlle Cohen(Royal Hallamshire Hospital), Virginia Haurigot(Spark Therapeutics (United States))
Cited by 2
Related Papers
TFEB Links Autophagy to Lysosomal Biogenesis
|Science|2011|3.3k
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
|Science Translational Medicine|2013|346
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
|Journal of Clinical Investigation|2013|232
Pros and cons for C4d as a biomarker
|Kidney International|2012|210